ID   EIF3E_HUMAN             Reviewed;         445 AA.
AC   P60228; O43902; Q64058; Q64059; Q64252; Q6FG33; Q8WVK4;
DT   16-JAN-2004, integrated into UniProtKB/Swiss-Prot.
DT   16-JAN-2004, sequence version 1.
DT   18-JUN-2025, entry version 207.
DE   RecName: Full=Eukaryotic translation initiation factor 3 subunit E {ECO:0000255|HAMAP-Rule:MF_03004};
DE            Short=eIF3e {ECO:0000255|HAMAP-Rule:MF_03004};
DE   AltName: Full=Eukaryotic translation initiation factor 3 subunit 6 {ECO:0000255|HAMAP-Rule:MF_03004};
DE   AltName: Full=Viral integration site protein INT-6 homolog;
DE   AltName: Full=eIF-3 p48 {ECO:0000255|HAMAP-Rule:MF_03004};
GN   Name=EIF3E {ECO:0000255|HAMAP-Rule:MF_03004};
GN   Synonyms=EIF3S6 {ECO:0000255|HAMAP-Rule:MF_03004}, INT6
GN   {ECO:0000255|HAMAP-Rule:MF_03004};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 280-289 AND 427-436,
RP   INTERACTION WITH EIF3A, IDENTIFICATION IN THE EIF-3 COMPLEX, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=9295280; DOI=10.1074/jbc.272.38.23477;
RA   Asano K., Merrick W.C., Hershey J.W.B.;
RT   "The translation initiation factor eIF3-p48 subunit is encoded by int-6, a
RT   site of frequent integration by the mouse mammary tumor virus genome.";
RL   J. Biol. Chem. 272:23477-23480(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Lung;
RX   PubMed=9403073; DOI=10.1006/geno.1997.4996;
RA   Miyazaki S., Imatani A., Ballard L., Marchetti A., Buttitta F.,
RA   Albertsen H., Nevanlinna H.A., Gallahan D., Callahan R.;
RT   "The chromosome location of the human homolog of the mouse mammary tumor-
RT   associated gene INT6 and its status in human breast carcinomas.";
RL   Genomics 46:155-158(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH TAX-1, SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=8688078; DOI=10.1126/science.273.5277.951;
RA   Desbois C., Rousset R., Bantignies F., Jalinot P.;
RT   "Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax
RT   oncoprotein.";
RL   Science 273:951-953(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH TAX-1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12386384; DOI=10.1007/bf02253422;
RA   Neuvert C., Jin D.-Y., Semmes O.J., Diella F., Callahan R., Jeang K.-T.;
RT   "Divergent subcellular locations of HTLV-I Tax and Int-6: a contrast
RT   between in vitro protein-protein binding and intracellular protein
RT   colocalization.";
RL   J. Biomed. Sci. 4:229-234(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-185.
RC   TISSUE=Bone marrow, Brain, Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-9; 60-71; 164-172; 256-265 AND 370-376, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Mammary carcinoma;
RA   Bienvenut W.V., Heiserich L., Gottlieb E., Matallanas D., Cooper W.N.,
RA   Kolch W.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [9]
RP   INTERACTION WITH EIF3C AND TRIM27, AND SUBCELLULAR LOCATION.
RX   PubMed=10504338; DOI=10.1242/jcs.112.19.3331;
RA   Morris-Desbois C., Bochard V., Reynaud C., Jalinot P.;
RT   "Interaction between the Ret finger protein and the Int-6 gene product and
RT   co-localisation into nuclear bodies.";
RL   J. Cell Sci. 112:3331-3342(1999).
RN   [10]
RP   INTERACTION WITH EIF3B.
RX   PubMed=11457827; DOI=10.1074/jbc.m102161200;
RA   Shalev A., Valasek L., Pise-Masison C.A., Radonovich M., Phan L.,
RA   Clayton J., He H., Brady J.N., Hinnebusch A.G., Asano K.;
RT   "Saccharomyces cerevisiae protein Pci8p and human protein eIF3e/Int-6
RT   interact with the eIF3 core complex by binding to cognate eIF3b subunits.";
RL   J. Biol. Chem. 276:34948-34957(2001).
RN   [11]
RP   INTERACTION WITH EIF3L.
RX   PubMed=11590142; DOI=10.1074/jbc.m104966200;
RA   Morris-Desbois C., Rety S., Ferro M., Garin J., Jalinot P.;
RT   "The human protein HSPC021 interacts with Int-6 and is associated with
RT   eukaryotic translation initiation factor 3.";
RL   J. Biol. Chem. 276:45988-45995(2001).
RN   [12]
RP   INTERACTION WITH COPS3; COPS6; COPS7 AND PSMC6.
RX   PubMed=12220626; DOI=10.1016/s0014-5793(02)03147-2;
RA   Hoareau Alves K., Bochard V., Rety S., Jalinot P.;
RT   "Association of the mammalian proto-oncoprotein Int-6 with the three
RT   protein complexes eIF3, COP9 signalosome and 26S proteasome.";
RL   FEBS Lett. 527:15-21(2002).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [14]
RP   CHARACTERIZATION OF THE EIF-3 COMPLEX.
RX   PubMed=15703437; DOI=10.1261/rna.7215305;
RA   Kolupaeva V.G., Unbehaun A., Lomakin I.B., Hellen C.U.T., Pestova T.V.;
RT   "Binding of eukaryotic initiation factor 3 to ribosomal 40S subunits and
RT   its role in ribosomal dissociation and anti-association.";
RL   RNA 11:470-486(2005).
RN   [15]
RP   INTERACTION WITH IFIT1.
RX   PubMed=16023166; DOI=10.1016/j.virol.2005.06.011;
RA   Terenzi F., Pal S., Sen G.C.;
RT   "Induction and mode of action of the viral stress-inducible murine
RT   proteins, P56 and P54.";
RL   Virology 340:116-124(2005).
RN   [16]
RP   INTERACTION WITH EIF4G1, IDENTIFICATION IN THE EIF-3 COMPLEX, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16766523; DOI=10.1074/jbc.m605418200;
RA   LeFebvre A.K., Korneeva N.L., Trutschl M., Cvek U., Duzan R.D.,
RA   Bradley C.A., Hershey J.W.B., Rhoads R.E.;
RT   "Translation initiation factor eIF4G-1 binds to eIF3 through the eIF3e
RT   subunit.";
RL   J. Biol. Chem. 281:22917-22932(2006).
RN   [17]
RP   INTERACTION WITH IFIT2.
RX   PubMed=16973618; DOI=10.1074/jbc.m605771200;
RA   Terenzi F., Hui D.J., Merrick W.C., Sen G.C.;
RT   "Distinct induction patterns and functions of two closely related
RT   interferon-inducible human genes, ISG54 and ISG56.";
RL   J. Biol. Chem. 281:34064-34071(2006).
RN   [18]
RP   FUNCTION, AND CHARACTERIZATION OF THE EIF-3 COMPLEX.
RX   PubMed=17581632; DOI=10.1038/sj.emboj.7601765;
RA   Masutani M., Sonenberg N., Yokoyama S., Imataka H.;
RT   "Reconstitution reveals the functional core of mammalian eIF3.";
RL   EMBO J. 26:3373-3383(2007).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH EIF3A; EIF3B; EIF3C; EIF4G1; NCBP1 AND UPF2.
RX   PubMed=17468741; DOI=10.1038/sj.embor.7400955;
RA   Morris C., Wittmann J., Jaeck H.-M., Jalinot P.;
RT   "Human INT6/eIF3e is required for nonsense-mediated mRNA decay.";
RL   EMBO Rep. 8:596-602(2007).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH EPAS1.
RX   PubMed=17324924; DOI=10.1074/jbc.m700423200;
RA   Chen L., Uchida K., Endler A., Shibasaki F.;
RT   "Mammalian tumor suppressor Int6 specifically targets hypoxia inducible
RT   factor 2 alpha for degradation by hypoxia- and pVHL-independent
RT   regulation.";
RL   J. Biol. Chem. 282:12707-12716(2007).
RN   [21]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-312.
RX   PubMed=17761670; DOI=10.1074/jbc.m706276200;
RA   Sha Z., Yen H.-C.S., Scheel H., Suo J., Hofmann K., Chang E.C.;
RT   "Isolation of the Schizosaccharomyces pombe proteasome subunit Rpn7 and a
RT   structure-function study of the proteasome-COP9-initiation factor domain.";
RL   J. Biol. Chem. 282:32414-32423(2007).
RN   [22]
RP   IDENTIFICATION IN THE EIF-3 COMPLEX, CHARACTERIZATION OF THE EIF-3 COMPLEX,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND MASS
RP   SPECTROMETRY.
RX   PubMed=17322308; DOI=10.1074/mcp.m600399-mcp200;
RA   Damoc E., Fraser C.S., Zhou M., Videler H., Mayeur G.L., Hershey J.W.B.,
RA   Doudna J.A., Robinson C.V., Leary J.A.;
RT   "Structural characterization of the human eukaryotic initiation factor 3
RT   protein complex by mass spectrometry.";
RL   Mol. Cell. Proteomics 6:1135-1146(2007).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH MCM7.
RX   PubMed=17310990; DOI=10.1038/sj.onc.1210314;
RA   Buchsbaum S., Morris C., Bochard V., Jalinot P.;
RT   "Human INT6 interacts with MCM7 and regulates its stability during S phase
RT   of the cell cycle.";
RL   Oncogene 26:5132-5144(2007).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-399, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   IDENTIFICATION IN THE EIF-3 COMPLEX, CHARACTERIZATION OF THE EIF-3 COMPLEX,
RP   MASS SPECTROMETRY, AND INTERACTION WITH EIF3B.
RX   PubMed=18599441; DOI=10.1073/pnas.0801313105;
RA   Zhou M., Sandercock A.M., Fraser C.S., Ridlova G., Stephens E.,
RA   Schenauer M.R., Yokoi-Fong T., Barsky D., Leary J.A., Hershey J.W.B.,
RA   Doudna J.A., Robinson C.V.;
RT   "Mass spectrometry reveals modularity and a complete subunit interaction
RT   map of the eukaryotic translation factor eIF3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:18139-18144(2008).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-399, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   INTERACTION WITH BZW2/5MP1.
RX   PubMed=21745818; DOI=10.1093/nar/gkr339;
RA   Singh C.R., Watanabe R., Zhou D., Jennings M.D., Fukao A., Lee B.,
RA   Ikeda Y., Chiorini J.A., Campbell S.G., Ashe M.P., Fujiwara T., Wek R.C.,
RA   Pavitt G.D., Asano K.;
RT   "Mechanisms of translational regulation by a human eIF5-mimic protein.";
RL   Nucleic Acids Res. 39:8314-8328(2011).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-399, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-442, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   FUNCTION, AND IDENTIFICATION IN THE EIF-3 COMPLEX.
RX   PubMed=25849773; DOI=10.1038/nature14267;
RA   Lee A.S., Kranzusch P.J., Cate J.H.;
RT   "eIF3 targets cell-proliferation messenger RNAs for translational
RT   activation or repression.";
RL   Nature 522:111-114(2015).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [37]
RP   FUNCTION.
RX   PubMed=27462815; DOI=10.1038/nature18954;
RA   Lee A.S., Kranzusch P.J., Doudna J.A., Cate J.H.;
RT   "eIF3d is an mRNA cap-binding protein that is required for specialized
RT   translation initiation.";
RL   Nature 536:96-99(2016).
RN   [38]
RP   3D-STRUCTURE MODELING, AND ELECTRON MICROSCOPY.
RX   PubMed=16322461; DOI=10.1126/science.1118977;
RA   Siridechadilok B., Fraser C.S., Hall R.J., Doudna J.A., Nogales E.;
RT   "Structural roles for human translation factor eIF3 in initiation of
RT   protein synthesis.";
RL   Science 310:1513-1515(2005).
CC   -!- FUNCTION: Component of the eukaryotic translation initiation factor 3
CC       (eIF-3) complex, which is required for several steps in the initiation
CC       of protein synthesis (PubMed:17581632, PubMed:25849773,
CC       PubMed:27462815). The eIF-3 complex associates with the 40S ribosome
CC       and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-
CC       tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The
CC       eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning
CC       of the mRNA for AUG recognition. The eIF-3 complex is also required for
CC       disassembly and recycling of post-termination ribosomal complexes and
CC       subsequently prevents premature joining of the 40S and 60S ribosomal
CC       subunits prior to initiation (PubMed:17581632). The eIF-3 complex
CC       specifically targets and initiates translation of a subset of mRNAs
CC       involved in cell proliferation, including cell cycling, differentiation
CC       and apoptosis, and uses different modes of RNA stem-loop binding to
CC       exert either translational activation or repression (PubMed:25849773).
CC       Required for nonsense-mediated mRNA decay (NMD); may act in conjunction
CC       with UPF2 to divert mRNAs from translation to the NMD pathway
CC       (PubMed:17468741). May interact with MCM7 and EPAS1 and regulate the
CC       proteasome-mediated degradation of these proteins (PubMed:17310990,
CC       PubMed:17324924). {ECO:0000255|HAMAP-Rule:MF_03004,
CC       ECO:0000269|PubMed:17310990, ECO:0000269|PubMed:17324924,
CC       ECO:0000269|PubMed:17468741, ECO:0000269|PubMed:17581632,
CC       ECO:0000269|PubMed:25849773, ECO:0000269|PubMed:27462815}.
CC   -!- SUBUNIT: Component of the eukaryotic translation initiation factor 3
CC       (eIF-3) complex, which is composed of 13 subunits: EIF3A, EIF3B, EIF3C,
CC       EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3J, EIF3K, EIF3L and
CC       EIF3M. The eIF-3 complex appears to include 3 stable modules: module A
CC       is composed of EIF3A, EIF3B, EIF3G and EIF3I; module B is composed of
CC       EIF3F, EIF3H, and EIF3M; and module C is composed of EIF3C, EIF3D,
CC       EIF3E, EIF3K and EIF3L. EIF3C of module C binds EIF3B of module A and
CC       EIF3H of module B, thereby linking the three modules. EIF3J is a labile
CC       subunit that binds to the eIF-3 complex via EIF3B. The eIF-3 complex
CC       interacts with RPS6KB1 under conditions of nutrient depletion.
CC       Mitogenic stimulation leads to binding and activation of a complex
CC       composed of MTOR and RPTOR, leading to phosphorylation and release of
CC       RPS6KB1 and binding of EIF4B to eIF-3. Interacts with COPS3, COPS6,
CC       COPS7 (COPS7A or COPS7B), EIF4G1, EPAS1, MCM7, NCBP1, PSMC6, TRIM27 and
CC       UPF2. Interacts with the HTLV-1 protein Tax-1. Interacts with IFIT1 and
CC       IFIT2 (PubMed:16023166, PubMed:16973618). Interacts with BZW2/5MP1
CC       (PubMed:21745818). {ECO:0000255|HAMAP-Rule:MF_03004,
CC       ECO:0000269|PubMed:10504338, ECO:0000269|PubMed:11457827,
CC       ECO:0000269|PubMed:11590142, ECO:0000269|PubMed:12220626,
CC       ECO:0000269|PubMed:12386384, ECO:0000269|PubMed:16023166,
CC       ECO:0000269|PubMed:16766523, ECO:0000269|PubMed:16973618,
CC       ECO:0000269|PubMed:17310990, ECO:0000269|PubMed:17322308,
CC       ECO:0000269|PubMed:17324924, ECO:0000269|PubMed:17468741,
CC       ECO:0000269|PubMed:18599441, ECO:0000269|PubMed:21745818,
CC       ECO:0000269|PubMed:25849773, ECO:0000269|PubMed:8688078,
CC       ECO:0000269|PubMed:9295280}.
CC   -!- INTERACTION:
CC       P60228; Q8IY42: C4orf19; NbExp=4; IntAct=EBI-347740, EBI-10216552;
CC       P60228; P04233: CD74; NbExp=2; IntAct=EBI-347740, EBI-2622890;
CC       P60228; P02489: CRYAA; NbExp=3; IntAct=EBI-347740, EBI-6875961;
CC       P60228; Q8IY21: DDX60; NbExp=2; IntAct=EBI-347740, EBI-2807346;
CC       P60228; Q14152: EIF3A; NbExp=18; IntAct=EBI-347740, EBI-366617;
CC       P60228; P55884: EIF3B; NbExp=9; IntAct=EBI-347740, EBI-366696;
CC       P60228; Q99613: EIF3C; NbExp=16; IntAct=EBI-347740, EBI-353741;
CC       P60228; O15371: EIF3D; NbExp=8; IntAct=EBI-347740, EBI-353818;
CC       P60228; Q9UBQ5: EIF3K; NbExp=9; IntAct=EBI-347740, EBI-354344;
CC       P60228; Q9Y262: EIF3L; NbExp=9; IntAct=EBI-347740, EBI-373519;
CC       P60228; Q99814: EPAS1; NbExp=10; IntAct=EBI-347740, EBI-447470;
CC       P60228; O95208-2: EPN2; NbExp=3; IntAct=EBI-347740, EBI-12135243;
CC       P60228; Q9HC44: GPBP1L1; NbExp=4; IntAct=EBI-347740, EBI-746674;
CC       P60228; Q5SUL5: HLA-A; NbExp=3; IntAct=EBI-347740, EBI-8561769;
CC       P60228; Q86U28: ISCA2; NbExp=3; IntAct=EBI-347740, EBI-10258659;
CC       P60228; Q92993: KAT5; NbExp=3; IntAct=EBI-347740, EBI-399080;
CC       P60228; Q5T749: KPRP; NbExp=3; IntAct=EBI-347740, EBI-10981970;
CC       P60228; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-347740, EBI-11742507;
CC       P60228; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-347740, EBI-2801965;
CC       P60228; Q6NTE8: MRNIP; NbExp=3; IntAct=EBI-347740, EBI-2857471;
CC       P60228; P06748: NPM1; NbExp=3; IntAct=EBI-347740, EBI-78579;
CC       P60228; P17252: PRKCA; NbExp=3; IntAct=EBI-347740, EBI-1383528;
CC       P60228; Q59EK9: RUNDC3A; NbExp=4; IntAct=EBI-347740, EBI-747225;
CC       P60228; Q59EK9-3: RUNDC3A; NbExp=3; IntAct=EBI-347740, EBI-11957366;
CC       P60228; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-347740, EBI-9090795;
CC       P60228; P14373: TRIM27; NbExp=7; IntAct=EBI-347740, EBI-719493;
CC       P60228; P61981: YWHAG; NbExp=3; IntAct=EBI-347740, EBI-359832;
CC       P60228; Q8IUH5: ZDHHC17; NbExp=2; IntAct=EBI-347740, EBI-524753;
CC       P60228; Q96MX3: ZNF48; NbExp=3; IntAct=EBI-347740, EBI-12006434;
CC       P60228; Q9Q2G4: ORF; Xeno; NbExp=5; IntAct=EBI-347740, EBI-6248094;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus, PML body.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Expressed at highest levels
CC       in appendix, lymph, pancreas, skeletal muscle, spleen and thymus.
CC       {ECO:0000269|PubMed:8688078, ECO:0000269|PubMed:9295280}.
CC   -!- MASS SPECTROMETRY: Mass=52131.8; Method=Unknown;
CC       Evidence={ECO:0000269|PubMed:17322308};
CC   -!- MASS SPECTROMETRY: Mass=52133.4; Mass_error=0.2; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:18599441};
CC   -!- SIMILARITY: Belongs to the eIF-3 subunit E family. {ECO:0000255|HAMAP-
CC       Rule:MF_03004}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U54562; AAC51760.1; -; mRNA.
DR   EMBL; U94174; AAC51917.1; -; Genomic_DNA.
DR   EMBL; U94162; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94163; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94164; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94165; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94166; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94167; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94168; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94169; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94170; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94171; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94172; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94173; AAC51917.1; JOINED; Genomic_DNA.
DR   EMBL; U94175; AAC51919.1; -; mRNA.
DR   EMBL; U62962; AAB58251.1; -; mRNA.
DR   EMBL; U85947; AAB88873.1; -; mRNA.
DR   EMBL; CR542275; CAG47071.1; -; mRNA.
DR   EMBL; CH471060; EAW91918.1; -; Genomic_DNA.
DR   EMBL; BC000734; AAH00734.1; -; mRNA.
DR   EMBL; BC008419; AAH08419.1; -; mRNA.
DR   EMBL; BC016706; AAH16706.1; -; mRNA.
DR   EMBL; BC017887; AAH17887.1; -; mRNA.
DR   EMBL; BC021679; AAH21679.1; -; mRNA.
DR   CCDS; CCDS6308.1; -.
DR   RefSeq; NP_001559.1; NM_001568.3.
DR   PDB; 3J8B; EM; -; E=1-395.
DR   PDB; 3J8C; EM; -; E=1-395.
DR   PDB; 6FEC; EM; 6.30 A; 3=1-445.
DR   PDB; 6YBD; EM; 3.30 A; v=1-445.
DR   PDB; 6ZMW; EM; 3.70 A; v=1-445.
DR   PDB; 6ZON; EM; 3.00 A; E=1-445.
DR   PDB; 6ZP4; EM; 2.90 A; E=1-445.
DR   PDB; 6ZVJ; EM; 3.80 A; E=2-430.
DR   PDB; 7A09; EM; 3.50 A; E=1-445.
DR   PDB; 7QP6; EM; 4.70 A; v=1-445.
DR   PDB; 7QP7; EM; 3.70 A; v=1-445.
DR   PDB; 8OZ0; EM; 3.50 A; 5=1-445.
DR   PDB; 8PJ1; EM; 3.40 A; v=1-445.
DR   PDB; 8PJ2; EM; 3.40 A; v=1-445.
DR   PDB; 8PJ3; EM; 3.70 A; v=1-445.
DR   PDB; 8PJ4; EM; 3.20 A; v=1-445.
DR   PDB; 8PJ5; EM; 2.90 A; v=1-445.
DR   PDB; 8PJ6; EM; 2.90 A; v=1-445.
DR   PDB; 8PPL; EM; 2.65 A; Iv=1-445.
DR   PDB; 8RG0; EM; 3.40 A; v=1-445.
DR   PDB; 8XXN; EM; 3.60 A; 3E=1-445.
DR   PDB; 9BLN; EM; 3.90 A; v=1-445.
DR   PDBsum; 3J8B; -.
DR   PDBsum; 3J8C; -.
DR   PDBsum; 6FEC; -.
DR   PDBsum; 6YBD; -.
DR   PDBsum; 6ZMW; -.
DR   PDBsum; 6ZON; -.
DR   PDBsum; 6ZP4; -.
DR   PDBsum; 6ZVJ; -.
DR   PDBsum; 7A09; -.
DR   PDBsum; 7QP6; -.
DR   PDBsum; 7QP7; -.
DR   PDBsum; 8OZ0; -.
DR   PDBsum; 8PJ1; -.
DR   PDBsum; 8PJ2; -.
DR   PDBsum; 8PJ3; -.
DR   PDBsum; 8PJ4; -.
DR   PDBsum; 8PJ5; -.
DR   PDBsum; 8PJ6; -.
DR   PDBsum; 8PPL; -.
DR   PDBsum; 8RG0; -.
DR   PDBsum; 8XXN; -.
DR   PDBsum; 9BLN; -.
DR   AlphaFoldDB; P60228; -.
DR   EMDB; EMD-10769; -.
DR   EMDB; EMD-11302; -.
DR   EMDB; EMD-11325; -.
DR   EMDB; EMD-11335; -.
DR   EMDB; EMD-11458; -.
DR   EMDB; EMD-11602; -.
DR   EMDB; EMD-14113; -.
DR   EMDB; EMD-14114; -.
DR   EMDB; EMD-17297; -.
DR   EMDB; EMD-17696; -.
DR   EMDB; EMD-17697; -.
DR   EMDB; EMD-17698; -.
DR   EMDB; EMD-17699; -.
DR   EMDB; EMD-17700; -.
DR   EMDB; EMD-17701; -.
DR   EMDB; EMD-17805; -.
DR   EMDB; EMD-19128; -.
DR   EMDB; EMD-38754; -.
DR   EMDB; EMD-4242; -.
DR   EMDB; EMD-44671; -.
DR   SMR; P60228; -.
DR   BioGRID; 109857; 278.
DR   ComplexPortal; CPX-6036; Eukaryotic translation initiation factor 3 complex.
DR   CORUM; P60228; -.
DR   DIP; DIP-32691N; -.
DR   FunCoup; P60228; 3597.
DR   IntAct; P60228; 142.
DR   MINT; P60228; -.
DR   STRING; 9606.ENSP00000220849; -.
DR   GlyGen; P60228; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P60228; -.
DR   MetOSite; P60228; -.
DR   PhosphoSitePlus; P60228; -.
DR   SwissPalm; P60228; -.
DR   BioMuta; EIF3E; -.
DR   DMDM; 41019126; -.
DR   jPOST; P60228; -.
DR   MassIVE; P60228; -.
DR   PaxDb; 9606-ENSP00000220849; -.
DR   PeptideAtlas; P60228; -.
DR   ProteomicsDB; 57190; -.
DR   Pumba; P60228; -.
DR   Antibodypedia; 13407; 305 antibodies from 33 providers.
DR   DNASU; 3646; -.
DR   Ensembl; ENST00000220849.10; ENSP00000220849.5; ENSG00000104408.11.
DR   GeneID; 3646; -.
DR   KEGG; hsa:3646; -.
DR   MANE-Select; ENST00000220849.10; ENSP00000220849.5; NM_001568.3; NP_001559.1.
DR   UCSC; uc003ymu.4; human.
DR   AGR; HGNC:3277; -.
DR   CTD; 3646; -.
DR   DisGeNET; 3646; -.
DR   GeneCards; EIF3E; -.
DR   HGNC; HGNC:3277; EIF3E.
DR   HPA; ENSG00000104408; Low tissue specificity.
DR   MalaCards; EIF3E; -.
DR   MIM; 602210; gene.
DR   OpenTargets; ENSG00000104408; -.
DR   VEuPathDB; HostDB:ENSG00000104408; -.
DR   eggNOG; KOG2758; Eukaryota.
DR   GeneTree; ENSGT00390000002661; -.
DR   InParanoid; P60228; -.
DR   OMA; NCPWILR; -.
DR   OrthoDB; 417252at2759; -.
DR   PAN-GO; P60228; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; P60228; -.
DR   PathwayCommons; P60228; -.
DR   Reactome; R-HSA-156827; L13a-mediated translational silencing of Ceruloplasmin expression.
DR   Reactome; R-HSA-72649; Translation initiation complex formation.
DR   Reactome; R-HSA-72689; Formation of a pool of free 40S subunits.
DR   Reactome; R-HSA-72695; Formation of the ternary complex, and subsequently, the 43S complex.
DR   Reactome; R-HSA-72702; Ribosomal scanning and start codon recognition.
DR   Reactome; R-HSA-72706; GTP hydrolysis and joining of the 60S ribosomal subunit.
DR   SignaLink; P60228; -.
DR   SIGNOR; P60228; -.
DR   BioGRID-ORCS; 3646; 690 hits in 1167 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; DEE660B4; Stress granule.
DR   ChiTaRS; EIF3E; human.
DR   EvolutionaryTrace; P60228; -.
DR   GeneWiki; EIF3S6; -.
DR   GenomeRNAi; 3646; -.
DR   Pharos; P60228; Tbio.
DR   PRO; PR:P60228; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P60228; protein.
DR   Bgee; ENSG00000104408; Expressed in calcaneal tendon and 211 other cell types or tissues.
DR   ExpressionAtlas; P60228; baseline and differential.
DR   GO; GO:0000785; C:chromatin; NAS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016282; C:eukaryotic 43S preinitiation complex; IEA:UniProtKB-UniRule.
DR   GO; GO:0033290; C:eukaryotic 48S preinitiation complex; IEA:UniProtKB-UniRule.
DR   GO; GO:0005852; C:eukaryotic translation initiation factor 3 complex; IDA:UniProtKB.
DR   GO; GO:0071540; C:eukaryotic translation initiation factor 3 complex, eIF3e; IEA:UniProtKB-UniRule.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0003743; F:translation initiation factor activity; IC:UniProtKB.
DR   GO; GO:0001732; P:formation of cytoplasmic translation initiation complex; NAS:ComplexPortal.
DR   GO; GO:0045947; P:negative regulation of translational initiation; NAS:UniProtKB.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; IMP:UniProtKB.
DR   GO; GO:1902416; P:positive regulation of mRNA binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0045727; P:positive regulation of translation; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0006446; P:regulation of translational initiation; ISS:UniProtKB.
DR   GO; GO:0006413; P:translational initiation; IDA:UniProtKB.
DR   CDD; cd21378; eIF3E; 1.
DR   HAMAP; MF_03004; eIF3e; 1.
DR   InterPro; IPR016650; eIF3e.
DR   InterPro; IPR019010; eIF3e_N.
DR   InterPro; IPR000717; PCI_dom.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR10317; EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT E; 1.
DR   Pfam; PF09440; eIF3_N; 1.
DR   Pfam; PF21357; EIF3E_C; 1.
DR   Pfam; PF01399; PCI; 1.
DR   PIRSF; PIRSF016255; eIF3e_su6; 1.
DR   SMART; SM01186; eIF3_N; 1.
DR   SMART; SM00088; PINT; 1.
DR   SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1.
DR   PROSITE; PS50250; PCI; 1.
DR   neXtProt; NX_P60228; -.
DR   PharmGKB; PA27705; -.
DR   TreeFam; TF101518; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Direct protein sequencing;
KW   Initiation factor; Nucleus; Phosphoprotein; Protein biosynthesis;
KW   Proteomics identification; Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03004,
FT                   ECO:0000269|PubMed:17322308, ECO:0000269|Ref.8,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..445
FT                   /note="Eukaryotic translation initiation factor 3 subunit
FT                   E"
FT                   /id="PRO_0000123515"
FT   DOMAIN          221..398
FT                   /note="PCI"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01185"
FT   REGION          4..128
FT                   /note="Sufficient for interaction with EPAS1"
FT                   /evidence="ECO:0000269|PubMed:17324924"
FT   REGION          9..195
FT                   /note="Sufficient for interaction with TRIM27"
FT                   /evidence="ECO:0000269|PubMed:10504338"
FT   REGION          351..445
FT                   /note="Sufficient for interaction with MCM7"
FT                   /evidence="ECO:0000269|PubMed:17310990"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03004,
FT                   ECO:0000269|PubMed:17322308, ECO:0000269|Ref.8,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         399
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         439
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P60229"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         445
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P60229"
FT   VARIANT         185
FT                   /note="A -> V (in dbSNP:rs17856554)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_046480"
FT   MUTAGEN         312
FT                   /note="L->D: Promotes nuclear accumulation."
FT                   /evidence="ECO:0000269|PubMed:17761670"
FT   HELIX           22..27
FT                   /evidence="ECO:0007829|PDB:8RG0"
FT   STRAND          35..37
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           38..41
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           50..54
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           62..65
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           67..69
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   STRAND          73..75
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           77..82
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            85..88
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            94..96
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           97..105
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           106..108
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            109..112
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           113..116
FT                   /evidence="ECO:0007829|PDB:8RG0"
FT   TURN            117..119
FT                   /evidence="ECO:0007829|PDB:8RG0"
FT   STRAND          122..124
FT                   /evidence="ECO:0007829|PDB:8RG0"
FT   TURN            126..128
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           129..137
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            148..152
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            162..164
FT                   /evidence="ECO:0007829|PDB:8RG0"
FT   HELIX           165..176
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            177..180
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           182..194
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           204..217
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   STRAND          222..224
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           225..228
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           229..231
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            232..234
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           238..244
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            245..248
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           251..263
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            271..275
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           276..279
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            280..284
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   STRAND          287..289
FT                   /evidence="ECO:0007829|PDB:8RG0"
FT   TURN            291..296
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            299..301
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           305..307
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   STRAND          308..312
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           315..320
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   STRAND          325..328
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           330..347
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   STRAND          348..350
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           353..356
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            359..361
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           364..376
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   TURN            377..379
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   STRAND          390..393
FT                   /evidence="ECO:0007829|PDB:8RG0"
FT   TURN            399..402
FT                   /evidence="ECO:0007829|PDB:6YBD"
FT   HELIX           403..419
FT                   /evidence="ECO:0007829|PDB:6YBD"
SQ   SEQUENCE   445 AA;  52221 MW;  A5368651DD0DDD0C CRC64;
     MAEYDLTTRI AHFLDRHLVF PLLEFLSVKE IYNEKELLQG KLDLLSDTNM VDFAMDVYKN
     LYSDDIPHAL REKRTTVVAQ LKQLQAETEP IVKMFEDPET TRQMQSTRDG RMLFDYLADK
     HGFRQEYLDT LYRYAKFQYE CGNYSGAAEY LYFFRVLVPA TDRNALSSLW GKLASEILMQ
     NWDAAMEDLT RLKETIDNNS VSSPLQSLQQ RTWLIHWSLF VFFNHPKGRD NIIDLFLYQP
     QYLNAIQTMC PHILRYLTTA VITNKDVRKR RQVLKDLVKV IQQESYTYKD PITEFVECLY
     VNFDFDGAQK KLRECESVLV NDFFLVACLE DFIENARLFI FETFCRIHQC ISINMLADKL
     NMTPEEAERW IVNLIRNARL DAKIDSKLGH VVMGNNAVSP YQQVIEKTKS LSFRSQMLAM
     NIEKKLNQNS RSEAPNWATQ DSGFY
//
